Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| May 1, 2025 | $0.15 | 2025-04-29 | 2025-04-29 |
Dividends Summary
- Consistent Payer: has rewarded shareholders with 1 dividend payments over the past 0 years.
- Total Returned Value: Investors who held CYCC shares during this period received a total of $0.15 per share in dividend income.
- Latest Payout: The most recent dividend of $0.15/share was paid 267 days ago, on May 1, 2025.
Company News
Cyclacel Pharmaceuticals reported preclinical study findings demonstrating that biliary tract cancer cells are sensitive to plogosertib, a PLK1 inhibitor, with potential for targeted cancer treatment using BUBR1 as a biomarker.
Cyclacel Pharmaceuticals has amended an exchange agreement with FITTERS Diversified Berhad to acquire all ordinary shares of Fitters Sdn. Bhd., issuing 19.99% of its stock and paying $1 million, with the transaction subject to stockholder approvals.
Cyclacel Pharmaceuticals published research showing its drug plogosertib could potentially treat fibrolamellar hepatocellular carcinoma (FLC), a rare liver cancer with no current approved treatments, primarily affecting adolescents and young adults.
Cyclacel Pharmaceuticals announced its Q1 2025 financial results, including a focus on the development of plogosertib and the deconsolidation of its UK subsidiary Cyclacel Limited. The company is exploring strategic alternatives to continue as a going concern, including a share exchange agreement with FITTERS Diversified Berhad.
Cyclacel Pharmaceuticals announced a change in control and leadership, with Datuk Dr. Doris Wong Sing Ee becoming the new CEO and Kiu Cu Seng appointed as Executive Director, Secretary and Chief Financial Officer.
